Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results
Spinal muscular atrophy (SMA) is a rare genetic disorder, with the most common form being 5q SMA. Survival of children with severe SMA is poor, yet major advances have been made in recent years in pharmaceutical treatment, such as gene-therapy, which has improved patient survival. Therefore, clinica...
Saved in:
Main Authors: | Venla Soini (Author), Gudrun Schreiber (Author), Bernd Wilken (Author), Anna Kathrin Hell (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spinal muscular atrophy - onasemnogene abeparvovec and other therapeutic options
by: Aleksandra Alicja Majchrzak-Celińska, et al.
Published: (2020) -
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
by: Charlotte A. René, et al.
Published: (2023) -
Short-Term Safety and Efficacy of Onasemnogene Abeparvovec in 10 Patients with Spinal Muscular Atrophy: Cohort Study
by: Kristina S. Nevmerzhitskaya, et al.
Published: (2021) -
Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations
by: Anna A. Kokorina, et al.
Published: (2023) -
Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational studyResearch in context
by: Claudia Weiß, et al.
Published: (2024)